Management of Chlamydia trachomatis genital tract infection: Screening and treatment challenges

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 19-29

  Taylor, Brandie D ^a   Haggerty, Catherine L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Chlamydia screening; Chlamydia trachomatis; Chlamydia treatment; Sexually transmitted disease

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; LEVOFLOXACIN; OFLOXACIN; RIFAMPICIN; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL URETHRITIS; CHLAMYDIASIS; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; FEMALE GENITAL TRACT INFECTION; HEALTH PROGRAM; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION RISK; MALE GENITAL TRACT INFECTION; MALE HOMOSEXUAL; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PREGNANCY OUTCOME; PROSTATITIS; REINFECTION; REVIEW; RISK REDUCTION; SCREENING TEST; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

EID: 79952679718     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S12715     Document Type: Review

References (135)

1. Stamm W. Chlamydia trachomatis infections of the adult. In: Homes K, Sparling P, Mardh P-A, et al, editors. Sexually Transmitted Diseases. New York, NY: McGraw Hill; 2008.
2. Holmes K, Handsfield H, Wang S, et al. Etiology of nongonococcal urethritis. N Engl J Med. 1975;292(23):1199-1205.
3. Oriel J, Reeve P, Powis P, Miller A, Nicol C. Chlamydia infection: Isolation of chlamydia from patients with non-specific genital infection. Br J Vener Dis. 1972;48(6):929-936.
4. Brunham R, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis. 1988;158(3):510-517.
5. Chow J, Yonekura M, Richwald G, et al. The association between Chlamydia trachomatis and ectopic pregnancy: A matched-pair, case- control study. JAMA. 1990;263(23):3164-3167.
6. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson S. Pelvic inflammatory disease and fertility: A cohort of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992;19(4):185-192.
7. Plummer F, Simonsen J, Cameron D, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991;163(2):233-239.
8. Madeleine M, Anttila T, Schwartz S, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer. 2007;120(3):650-655.
9. Brocklehurst P, Rooney G. Interventions for treating genital Chlamydia trachomatis infection in pregnancy (review). Cochrane Database Syst Rev. 2000;2:CD000054.
10. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: Overview and estimates. Available from: http://whqlibdoc.who.int/hq/2001/WHO_HIV_AIDS_2001.02.pdf. Accessed Jul 15, 2010.
11. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6-10.
12. Patel A, Rashid S, Godfrey E, Panchal H. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae genital infections in a publicly funded pregnancy termination clinic: Empiric vs. indicated treatment? Contraception. 2008;78(4):328-331.
13. Schachter J, Hanna L, Hill EC, et al. Are chlamydial infections the most prevalent venereal disease? JAMA. 1974;57(12):1252-1255.
14. Imai H, Nakao H, Shinohara H, et al. Population-based study of asymptomatic infection with Chlamydia trachomatis among female and male students. Int J STD AIDS. 2010;21(5):362-366.
15. Satterwhite C, Tian L, Braxton J, Weinstock H. Chlamydia prevalence among women and men entering the National Job Training Program: United States, 2003-2007. Sex Transm Dis. 2010;37(2):63-74.
16. Quinn T, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partners. JAMA. 1996;476(21):1737-1742.
17. Forhan S, Gottlieb S, Sternberg M, et al. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics. 2009;124(6):1505-1512.
18. Turner C, Rogers S, Miller H, et al. Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA. 2002; 287(6):726-733.
19. Miller W, Ford C, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA. 2004;291(18):2229-2236.
20. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2008. Atlanta, GA: US Department of Health and Human Services; 2009.
21. European Centre for Disease Prevention and Control. Chlamydia control in Europe. Stockholm, 2009. Available from: http://www.ecdc.europa.eu/en/publications/Publications/0906_GUI_Chlamydia_Control_in_Europe.pdf. Accessed Jul 20, 2010.
22. Hocking J, Walker J, Regan D, Chen M, Fairley C. Chlamydia screening - Australia should strive to achieve what others have not. Med J Aust. 2008;188(2)106-108.
23. Health Protection Agency. Sexually transmitted infections and young People in the United Kingdom: 2008 Report. 2008 Jul. Available from: http://www.hpa.org.uk/hpr/archives/2009/news2909.htm. Accessed Dec 18, 2010.
24. Fenton K, Lowndes C. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect. 2004; 80(4):255-263.
25. Public Health Agency of Canada. Brief report on sexually transmitted infections in Canada: 2007. Available from: http://www.phac-aspc.gc.ca/publicat/2009/sti-its/pdf/sti_brief-its_bref_2009-eng.pdf. Accessed Jul 22, 2010.
26. Brunham R, Pourbohloul B, Mak S, White R, Rekart M. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192(10): 1836-1844.
27. Low N. Screening programs for chlamydial infection: When will we ever learn? BMJ. 2007;334(7596):725-728.
28. Gotz H, Lindback J, Ripa T, Arneborn M, Ramstedt K, Ekdahl K. Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods? Scand J Infect Dis. 2002;34(1):28-34.
29. Vickers D, Osgood N. Current crisis of artifact of surveillance: Insights into rebound chlamydia rates from dynamic modeling. BMC Infect Dis. 2010;10:70.
30. Rekart M, Brunham R. Epidemiology of chlamydial infection: Are we losing ground? Sex Transm Infect. 2008:84(2):87-91.
31. Low N. Caution: Chlamydia surveillance data ahead. Sex Transm Infect. 2008;84(2):80-81.
32. Moss N, Ahrens K, Kent C, Klausner J. The decline in clinical sequelae of genital Chlamydia trachomatis infection supports current control strategies. J Infect Dis. 2006;193(9):1336-1338.
33. Karam G, Martin D, Flotte T, et al. Asymptomatic Chlamydia trachomatis infections among sexually active men. J Infect Dis. 1986; 154(5):900-903.
34. Zimmerman H, Potterat J, Dukes R, et al. Epidemiologic differences between chlamydia and gonorrhea. Am J Public Health. 1990;80(11): 1338-1342.
35. Stamm W, Koutsky L, Benedetti J, Jourden J, Brunham R, Holmes K. Chlamydia trachomatis urethral infections in men. Prevalence, risk factors, and clinical manifestations. Ann Intern Med. 1984;100(1): 47-51.
36. Takahashi S, Takeyama K, Kunishima Y, et al. Analysis of clinical manifestations of male patients with urethritis. J Infect Chemother. 2006;12(5):286-286.
37. Yu J, Tang W, Lau K, Chong L, Lo K. Asymptomatic urethral infection in male sexually transmitted disease clinic attendees. Int J STD AIDS. 2008;19(3):155-158.
38. Gaydos C, Maldeis N, Hardick A, Hardick J, Quinn T. Mycoplasma genitalium compared to chlamydia, gonorrhea and trichomonas as an aetiological agent of urethritis in men attending STD clinics. Sex Transm Infect. 2009;83(6):438-440.
39. Bradshaw C, Tabrizi S, Read T, et al. Etiologies of nongonococcal urethritis: Bacteria, viruses, and the association with orogenital exposure. J Infect Dis. 2006;193(3):336-345.
40. Berger R, Alexander E, Monda G, Ansell J, McCormick G, Holmes K. Chlamydia trachomatis as a cause of acute "idiopathic" epididymitis. N Engl J Med. 1978;298(6):301-304.
41. Berger R, Alexander E, Harnisch J, et al. Etiology, manifestations and therapy of acute epididymitis: Prospective study of 50 cases. J Urol. 1979;121(6):750-754.
42. Redfern T, English P, Baumber C, McGhie D. The aetiology and management of acute epididymitis. Br J Surg. 1984;71(9):703-705.
43. Trojian T, Lishnak T, Heiman D. Epididymitis and orchitis: An overview. Am Fam Physician. 2009;79(7):583-587.
44. Melekos M, Asbach H. The role of chlamydiae in epididymitis. Int Urol Nephrol. 1988;20(3):293-297.
45. Martin-Iguacel R, Llibre J, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: A silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis. 2010;29(8):917-925.
46. Badalyan R, Fanarjyan S, Aghajanyan I. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia. 2003;35(5):263-265.
47. Motrich R, Cuffini C, Oberti J, Maccioni M, Rivero V. Chlamydia trachomatis occurrence and its impact on sperm quality in chronic prostatitis patients. J Infect. 2006;53(3):175-183.
48. Zdrodwska-Stefanow B, Ostaszewska-Puchalska I, Badyda J, Galewska Z. The evaluation of markers of prostatic inflammation and function of the prostate gland in patients with chronic prostatitits. Arch Immunol Ther Exp. 2008;56(4):277-282.
49. Zdrodwska-Stefanow B, Ostaszewska-Puchalska I, Badyda J, Galewska Z. The effect of Chlamydia trachomatis infection of the prostate gland on the concentration of citric acid. Arch Immunol Ther Exp. 2006;54(1):69-73.
50. Ouzounova-Raykova V, Ouzounova I, Mitov I. May Chlamydia trachomatis be an aetiological agent of chronic prostatic infection? Andrologia. 2010;42(3):176-181.
51. Poletti F, Medici M, Alinovi A, et al. Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis. J Urol. 1985;134(4):691-693.
52. Shurbaji M, Gupta P, Myers J. Immunohistochemical demonstration of Chlamydia antigens in association with prostatitis. Mod Pathol. 1988;1(5):348-351.
53. Abdelatif O, Chandler F, McGuire B. Chlamydia trachomatis in chronic abacterial prostatitis: Demonstration by colorimetric in situ hybridization. Hum Pathol. 1991;22(1):41-44.
54. Corradi G, Bucsek M, Panovics J, et al. Detection of Chlamydia trachomatis in the prostate by in-situ hybridization and by transmission electron microscopy. Int J Androl. 1996;19(2):109-112.
55. Weidner W, Diemer T, Huwe P, Rainer H, Ludwig M. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents. 2002; 19(6):466-470.
56. Kreiger J, Riley D. title typecontributorChronic prostatitis: Charlottesville to Seattle. J Urol. 2004;172(6 Pt 2):2557-2560.
57. Trei J, Canas L, Gould P. Reproductive tract complications associated with Chlamydia trachomatis infection in US Air Force Males within 4 years of testing. Sex Transm Dis. 2008;35(9):827-833.
58. Weidner W, Schiefer H, Krauss H, Jantos C, Friedrick H, Altmannsberger M. Chronic prostatitis: A thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991;19 Suppl 3:119-125.
59. Doble A, Thomas B, Walker M, Harris J, Witherow R, Taylor-Robinson D. The role of Chlamydia trachomatis in chronic abacterial prostatitis: A study using ultrasound guided biopsy. J Urol. 1989;141(2): 332-333.
60. Paavonen J, Eggert-Kruse W. title typecontributorChlamydia trachomatis: Impact on human reproduction. Hum Reprod Update. 1999;5(5):433-447.
61. Eggert-Kruse W, Buhlinger-Gopfarth N, Rohr G, et al. Antibodies to Chlamydia trachomatis in semen and relationship with parameters of male fertility. Hum Reprod. 1996;11(7):1408-1417.
62. Mazzoli S, Cai T, Addonisio P, Bechi A, Mondaini N, Bartoletti R. Chlamydia trachomatis infection is related to poor semen quality in young prostatitis patients. Eur Urol. 2010;57(4):708-714.
63. Ouzounova-Raykova V, Ouzounova I, Mitov I. Chlamydia trachomatis infection as a problem among male partners of infertile couples. Andrologia. 2009;41(1):14-19.
64. Ness R, Markovic N, Carlson C, Coughlin M. Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Fertil Steril. 1997;68(2):205-213.
65. Eggert-Kruse W, Rohr G, Demirakca T, et al. Chlamydial serology in 1303 asymptomatic subfertile couples. Hum Reprod. 1997;12(7): 1464-1475.
66. Fung M, Scott K, Kent C, et al. Chlamydia and gonorrhea re-infection among males: A systematic review of data to evaluate the need for re-testing. Sex Transm Infect. 2007;83(4):304-309.
67. Marazzo J, Martin D. Management of women with cervicitis. Clin Infect Dis. 2007;44 Suppl 3:S102-S110.
68. Brunham R, Paavonen J, Stevens C, et al. Mucopurulent cervicitis - the ignored counterpart of urethritis in men. N Engl J Med. 1984; 158(1):510-517.
69. Stamm W, Wagner K, Amsel R, et al. Causes of the acute urethral syndrome in women. N Engl J Med. 1980;303(8):409-415.
70. Wallin J, Thompson S, Zaidi A, Wong K. Urethritis in women attending an STD clinic. Br J Vener Dis. 1981;57(1):50-54.
71. Wolner-Hanssen P, Mardh P. In vitro tests of the adherence of Chlamydia trachomatis to human spermatozoa. Fertil Steril. 1984;42(1):102-107.
72. Friberg J, Confino E, Suarez M, Gleicher N. Chlamydia trachomatis attached to spermatozoa recovered from the peritoneal cavity of patients with salpingitis. J Reprod Med. 1987;32(2):120-122.
73. Zervomanolakis I, Ott H, Hadziomerovic D, et al. Physiology of upward transport in the human female genital tract. Ann N Y Acad Sci. 2007;1101:1-20.
74. Paavonen J, Westrom L, Eschenbach D. Pelvic inflammatory disease. In: Holmes K, Sparling P, Mardh P-A, et al, editors. Sexually Transmitted Diseases. New York, NY: McGraw Hill; 2008.
75. Ijland M, Evans J, Dunselman G, Hoogland H. Subendometrial contractions in the nonpregnant uterus: An ultrasound study. Eur J Obstet Gynecol Reprod Biol. 1996;70(1):23-24.
76. Ness R, Soper D, Holley R, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the PID Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol. 2002;186(5):929-937.
77. Heinonen P, Meittinen A. Laporscopic study on the microbiology and severity of acute pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol. 1994;57(2):85-89.
78. Ness R, Randall H, Richter H, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health. 2004;94(8):1327-1329.
79. Haggerty C, Hillier S, Bass D, Ness R. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis. 2004;39(7):990-995.
80. Haggerty C, Ness R, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol. 2003;188(1):141-148.
81. Eckert L, Hawes S, Wolner-Hanssen P, et al. Endometritis: The clinicalpathologic syndrome. Am J Obstet Gynecol. 2002;186(4):690-695.
82. Weisenfeld H, Hillier S, Krohn M, et al. Lower genital tract infection and endometritis: Insight into subclinical pelvic inflammatory disease. Obstet Gynecol. 2002;100(3):456-463.
83. Ripa K, Sensson L, Treharne J, Westrom L, Mardh P. Chlamydia trachomatis infection in patients with laparoscopically verified acute salpingitis. Results of isolation and antibody determinations. Am J Obstet Gynecol. 1980;138(7 Pt 2):960-964.
84. Taylor-Robinson D, Stacey C, Jensen J, Thomas B, Munday P. Further observations, mainly serological, on a cohort of women with and without pelvic inflammatory disease. Int J STD AIDS. 2009;20(10): 712-718.
85. Bevan C, Johal B, Mumtaz G, Ridgway G, Siddle N. Clinical, laparoscopic and microbiological findings in acute salpingitis: Report on a United Kingdom cohort. Br J Obstet Gynecol. 1995;102(5): 407-414.
86. Hook W III, Spitters C, Reichart C, Neumann T, Quinn T. Use of cell culture and rapid diagnostic assay for Chlamydia trachomatis screening. JAMA. 1994;272(11):867-870.
87. Geisler W, Wang C, Morrison S, Black C, Bandea C, Hook EW III. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis. 2008;35(2):119-123.
88. Bachmann L, Richey C, Waites K, Schwebke J, Hook W III. Patterns of Chlamydia trachomatis testing and follow-up at a University Hospital Medical Center. Sex Transm Dis. 1999;26(9):496-509.
89. Morre S, van den Brule A, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year of follow-up. Int J STD AIDS. 2002; 13 Suppl 2:12-18.
90. Rahm V, Belsheim J, Gleerup A, Gnarpe H, Rosen G. Asymptomatic carriage of Chlamydia trachomatis: A study of 109 teenage girls. Eur J Sex Transm Dis. 1986;3:91-94.
91. Bakken I, Ghaderi S. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: A historical follow-up study. BMC Infect Dis. 2009;9:130.
92. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: The POPI (Prevention Of Pelvic Infection) trial. BMJ. 2010; 340:c1642.
93. Ness R, Smith K, Chang C, Schisterman E, Bass D. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex Transm Dis. 2006;33(3):137-142.
94. Brunham R, Maclean I, Binns B, Peeling R. Chlamydia trachomatis: Its role in tubal infertility. J Infect Dis. 1985;152(6):1275-1282.
95. Miettinen A, Heinonen P, Teisala K, Hakkarainen K, Punnonen R. Serologic evidence for the role of Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma hominis in the etiology of tubal factor infertility and ectopic pregnancy. Sex Transm Dis. 1990;17(1):10-14.
96. Toye B, Laferriere C, Claman P, Jessamine P, Peeling R. Association between antibody to the chlamydial heat shock protein and tubal infertility. J Infect Dis. 1993;168(5):1236-1240.
97. Tiitinen A, Surcel H, Halttunen M, et al. Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell- mediated responses predict tubal factor infertility. Hum Reprod. 2006;21(6): 1533-1538.
98. Brunham R, Peeling R, MacLean I, Kosseim M, Paraskevas M. Chlamydia trachomatis-associated ectopic pregnancy: Serological and histological correlates. J Infect Dis. 1992;165(6):1076-1081.
99. Sziller I, Witkin S, Ziegert M, Csapo Z, Ujhazy A, Papp Z. Serological responses of patients with ectopic pregnancy to epitopes of the Chlamydia trachomatis 60 kDa heat shock protein. Hum Reprod. 1998;13(4):1088-1093.
100. Safrin S, Schachter J, Dahrouge D, Sweet R. Long-term sequelae of acute pelvic inflammatory disease. A retrospective cohort study. Am J Obstet Gynecol. 1992;166(4):1300-1305.
101. Evans C, Das C, Kinghorn G. A retrospective study of recurrent chlamydia infection in men and women: Is there a role for targeted screening for those at risk? Int J STD AIDS. 2009;20(3):188-192.
102. Skjeldestad F, Marsico M, Sings H, Nordbo S, Storvold G. Incidence and risk factors for genital Chlamydia trachomatis infection: A 4-year prospective cohort study. Sex Transm Dis. 2009;36(5):273-279.
103. Kimani J, Maclean I, Bwayo J, et al. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J Infect Dis. 1996;173(6):1437-1444.
104. Ness R, Soper D, Richter H, et al. Chlamydia antibodies, chlamydia heat shock protein and adverse sequelae after pelvic inflammatory disease: The PID Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis. 2008;35(2):129-135.
105. Low N, Bender N, Nartey L, Shang A, Stephenson J. Effectiveness of chlamydia screening: Systematic review. Int J Epidemiol. 2009;38(2): 435-448.
106. Howell M, Quinn T, Gaydos C. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. As cost-effectiveness analysis of three strategies. Ann Intern Med. 1998; 128(4):277-284.
107. Welte R, Kretzschmar M, Leidl R, van den Hoek A, Jager J, Postma M. Cost-effectiveness of screening programs for Chlamydia trachomatis: A population-based dynamic approach. Sex Transm Dis. 2000; 27(9):518-529.
108. Goeree R, Jang D, Blackhouse G, et al. Cost-effectiveness of screening swab or urine specimens for Chlamydia trachomatis from young Canadian women in Ontario. Sex Transm Dis. 2001;28(12):701-709.
109. Hu D, Hook E, Goldie S. Screening for Chlamydia trachomatis in women 15 to 29 years of age: A cost effectiveness analysis. Ann Intern Med. 2004;141(7):501-513.
110. Land J, van Bergen J, Morre S, Postma M. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update. 2010;16(2):189-204.
111. Van Valkengoed I, Morre S, van den Brule A, Meijer C, Bouter L, Boeke A. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes - implications for cost-effectiveness analysis. Int J Epidemiol. 2004;33(2):416-425.
112. Hu D, Hook E, Goldie S. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies. Sex Transm Dis. 2006;33(7):428-436.
113. Roberts T, Robinson S, Barton P, et al. Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: Economic evaluation of chlamydia screening studies (ClaSS) project. BMJ. 2007;335(7614):291.
114. Adams E, Turner K, Edmunds W. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect. 2007;83(4):267-274.
115. Østergaard L, Anderson B, Olesen F, Møller J. Efficacy of home sampling for screening of Chlamydia trachomatis: Randomised study. BMJ. 1998;317(7150):26-27.
116. Herlitz C, Steel J. A decade of HIV/AIDS prevention in Sweden: Changes in attitudes associated with HIV and sexual risk behavior from 1987 to 1997. AIDS. 2000;14(7):881-890.
117. Burstein G, Zenilman J, Gaydos C, et al. Predictors of repeat Chlamydia trachomatis infections diagnosed by DNA amplification testing among inner city females. Sex Transm Infect. 2001;77(1):26-32.
118. Niccolai L, Hochberg A, Ethier K, Lewis J, Ickovics J. Burden of recurrent Chlamydia trachomatis infections in young women: Further uncovering the "hidden epidemic". Arch Pediatr Adolesc Med. 2007; 161(3):246-251.
119. Whittington W, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: Results of a multicenter cohort study. Sex Transm Dis. 2001;28(2): 117-123.
120. Scholes D, Stergachis A, Heidrich F, Andrilla H, Holmes K, Stamm W. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334(21):1362-1366.
121. Østergaard L, Anderson B, Møller, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: A cluster-randomized 1 year follow-up study. Clin Infect Dis. 2000;31(4):951-957.
122. Haggerty C, Peipert J, Weitsen S, et al. Predictors of chronic pelvic pain in an urban population of women with symptoms and signs of pelvic inflammatory disease. Sex Transm Dis. 2005;32(5):293-299.
123. Centers for Disease Control. Sexually transmitted diseases treatment guidelines. Morbid Mortal Wkly Rep. 2010;55:79-85.
124. Schachter J. Rifampin in chlamydial infections. Rev Infect Dis. 1983; 5 Suppl 3:S562-S564.
125. Schachter J, Stephens R. Biology of Chlamydia trachomatis. In: Homes K, Sparling P, Mardh P-A, et al, editors. Sexually Transmitted Diseases. New York, NY: McGraw Hill; 2008.
126. Lau C, Qureshi A. Azithromycin versus doxycycline for genital chlamydial infections: A meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29(9):497-502.
127. Pal S, Peterson E, de la Maza L. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005;73(12):8153-8160.
128. Pal S, Peterson E, Rappuoli R, Ratti G, de la Maza L. Immunization of the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against genital challenge. Vaccine. 2006;24(6): 766-775.
129. Shaw J, Grund V, Durling L, Crane D, Caldwell H. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4(.) type 2 rather than type 1 immune response that is not protective. Infect Immun. 2002;70(3):1097-1105.
130. Pal S, Theodor I, Peterson E, de al Maza L. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001;69(10):6240-6247.
131. Zhang D, Yang X, Berry J, Shen C, McClarty G, Brunham R. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis. 1997;176(4):1035-1040.
132. Wehrl W, Brinkman V, Jungblut P, Meyer T, Szczepek A. From the inside out - processing of the chlamydial autotransporter PmpD and its role in bacterial adhesion and activation of human host cells. Mol Microbiol. 2003;51(2):319-334.
133. Niessner A, Kaun C, Zorn G, et al. Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kB pathway. J Infect Dis. 2003;188(1): 108-113.
134. Crane D, Carlson J, Fischer E, et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci U S A. 2006;103(6):1894-1899.
135. Tan C, Hsia R, Shou H, Carrasco J, Rank R, Bavoil P. Variable expression of surface-exposed polymorphic membrane proteins in in vitro-grown Chlamydia trachomatis. Cell Microbiol. 2010;12(2): 174-187.